Patricia Pozo Rosich (Headache Unit and Headache Research Group, Vall d’Hebron University Hospital, Barcelona, Spain) talks to us about unmet needs of migraine prevention in Europe and the calcitonin gene-related peptide receptor antagonist, erenumab, in light of it recently receiving a positive CHMP opinion for this indication.
1. What are the major unmet needs of migraine prevention in Europe? (0:12)
2. What is the mechanism of action of erenumab? (0:50)
3. How is erenumab administered? (1:44)
4. Could you tell us a little about the evidence base for the positive CHMP opinion for erenumab for the prevention of migraine? (2:08)
5. Which patients are most likely to benefit from erenumab? (2:39)
Speaker disclosure: Patricia Pozo Rosich serves as a speaker/adviser for Allergan, Almirall, Chiesi, Novartis, Teva and Lilly; she also receives grant support from Allergan.
Filmed at the 4th Congress of the European Academy of Neurology (EAN), Lisbon, Portugal, June 2018.
Share this Video
Related Videos In Headache Disorders
Serena Orr, AHS 2021: Stress and Peak Pain Severity in Chronic Migraine
We had the great pleasure of meeting with Dr. Serena Orr (Hotchkiss Brain Institute, University of Calgary, Calgary, Canada) to discuss the relationship between peak pain severity in chronic migraine, and its relationship to stress. The abstract ‘The Relationship Between Perceived Stress and Peak Pain Severity in Individuals with Chronic Migraine: A Longitudinal Cohort Study […]
Andrew Blumenfeld, AHS 2021: Combination use of OnabotulinumtoxinA and CGRP mAbs for Chronic Migraine
We had the great pleasure of meeting with Andrew Blumenfeld (Director, Headache, The Neurology Center of Southern California, Carlsbad, CA, USA) to discuss the combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine. The abstract ‘Combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine’ was presented at […]
Richard Lipton, AHS 2021: COURAGE Study Results
touchNEUROLOGY met with Richard Lipton (Albert Einstein College of Medicine, Bronx, NY, USA) to discuss the COURAGE study results investigating the Migraine Buddy Application. The abstract ‘Combining UbRogepAnt and Preventives for MiGrainE (COURAGE) Study Using the Migraine Buddy Application: A Novel, Entirely Remote Design for Collecting Real-world Evidence’ was presented at the American Headache Society […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!